about
Targeting folate receptor alpha for cancer treatmentMolecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and TreatmentPlasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer.Sustained epidermal powder drug delivery via skin microchannels.From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.Cancer immunotherapies targeting the PD-1 signaling pathway.Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium.Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides.Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancerRegulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
P2860
Q26744215-EE371449-CDEA-44E5-B2B8-ACD53E3353C5Q28066904-4B6DA506-44C4-40B1-9B7F-DBDBBC21D256Q33660646-7CCB5E45-218E-4EDE-B04C-CF7B0DF2DD6FQ36263427-5D543A9F-9F96-4857-9D13-9903578C3482Q37642460-71F4BA7C-C8D7-4659-B6EA-0ADF48D8612BQ37737940-75D9F091-E6A7-4350-8CCF-84E941B54B1BQ38693066-832E6740-F9EB-4A5F-A1F3-33DBB34688DAQ39402079-B4C4E15E-049E-4FAD-8422-FBE150358E90Q41006936-548B460C-BBF9-49FA-BD55-8C38C09422BCQ45064344-3C18DB40-9BB2-4E50-AABB-3F4F2E50AA27Q47820348-0617E636-7063-4618-8968-A6853E2DCEEEQ51092888-936A861B-8C27-4A21-9014-58B6ADE2A017Q52582442-849F88D1-CC23-446A-AB43-2AF56DF68FF8Q52730115-FDCB8DF0-0142-4C71-B3A1-6F737357BB63Q55282202-0B1DD6E1-E0D6-4597-9440-90345C699045Q58703256-BC0D910B-8510-49D3-A2D0-B4B9A920659DQ58773649-80C0C418-73F7-4C28-9E2F-0CBBBABE2A6C
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Immune checkpoint inhibition in ovarian cancer.
@en
type
label
Immune checkpoint inhibition in ovarian cancer.
@en
prefLabel
Immune checkpoint inhibition in ovarian cancer.
@en
P2093
P2860
P356
P1476
Immune checkpoint inhibition in ovarian cancer.
@en
P2093
Ikuo Konishi
Junzo Hamanishi
Masaki Mandai
P2860
P304
P356
10.1093/INTIMM/DXW020
P577
2016-04-07T00:00:00Z